Roberto Accolla

Roberto Accolla is a Professor in the field of Immunology and Molecular Biology, known for his groundbreaking work on immune response regulation, cancer immunotherapy, and virology. His research has significantly advanced understanding of MHC-II regulation via CIITA, HTLV-1 pathogenesis, and mucosal immunity in vaccine responses.

• Education: MD, cum laude, Sapienza University of Rome (1974)
• Postdoctoral Fellowship: Department of Pathology, University of Pennsylvania (1975-1976)

Research Focus: Current work spans cancer immunotherapy, viral immunology (HTLV-1), and vaccine development. His studies on CIITA's role in adaptive and intrinsic immunity have been published in high-impact journals like Biomedical Journal and Frontiers in Immunology. He has also contributed to clinical trials for therapeutic cancer vaccines.

• 2023: CIITA's dual role in immunity and cancer
• 2022: Glioblastoma organoid immunotherapy
• 2022: HepaVac-101 vaccine trial for liver cancer

Editorial Contributions: Active Associate Editor for Frontiers in Immunology, supporting open-access research.